1.0Novaptechhttps://novaptech.com/enrich600338<blockquote class="wp-embedded-content" data-secret="qTvy8aX2uM"><a href="https://novaptech.com/en/portfolio_page/aptamers-as-therapeutics/">Aptamers as therapeutics</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://novaptech.com/en/portfolio_page/aptamers-as-therapeutics/embed/#?secret=qTvy8aX2uM" width="600" height="338" title="“Aptamers as therapeutics” — Novaptech" data-secret="qTvy8aX2uM" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script> /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); //# sourceURL=https://novaptech.com/wp-includes/js/wp-embed.min.js </script> Aptamers as therapeutics Aptamers have a huge potential as therapeutic agents. They can be addressed to intracellular targets, to membrane components or to circulating molecules. They can be used as drug-delivery agents to cells of interest. They can be employed as antagonists (preventing a specific receptor-ligand interaction), or as agonists (binding to a receptor and activating a signal). Aptamers can be easily modified for improving their properties (making them more resistant to nucleases or increasing their in vivo half-life). They induce a minimal immune response in vivo. Several clinical trials are on-going. Novaptech contributes to this field; see for instance :  Millozzi, F., Milán-Rois, P., Sett, A., Delli Carpini, G., De Bardi, M., Gisbert-Garzarán, M., Sandonà, M., Rodríguez-Díaz, C., Martínez-Mingo, M., Pardo, I., Esposito, F., Viscomi, M. T., Bouché, M., Parolini, O., Saccone, V., Toulmé, J.-J., Somoza, Á., & Palacios, D. (2025). Aptamer-conjugated gold nanoparticles enable oligonucleotide delivery into muscle stem cells to promote regeneration of dystrophic muscles. Nature Communications, 16, Article 577.